glutaminase gls1 (kga)

IPN60090是一种新型、强效、口服生物利用度高的 肾型谷氨酰胺酶（GLS1）特异性抑制剂，对GLS1的IC50值为31 nM。IPN60090 具有潜在的抗癌和免疫刺激 免疫调节活性，可选择性地靶向、结合并抑制人谷氨酰胺酶，可用于研究 GLS1 介导的疾病。

BPTES 是一种特异性 GlutamiN Ase GLS1 (KGA) 抑制剂，IC50=0.16 μM。

Glutaminase-IN-1 (CB839 derivative)，是一种新型 1,3,4-硒二氮基肾型谷氨酰胺酶(KGA) 的变构抑制剂，在侵袭性 H22 肝癌异种移植模型中显示出抗肿瘤活性。

Telaglenastat (CB-839) hydrochloride is a first-in-class, reversible, and orally active inhibitor of glutaminase 1 (GLS1). It selectively inhibits the splice variants of GLS1, specifically KGA (kidney-type glutaminase) and GAC (glutaminase C), as compared to GLS2. Telaglenastat hydrochloride has an IC50 of 23 nM for endogenous glutaminase in mouse kidney and 28 nM in the brain. In addition, it induces autophagy and exhibits antitumor activity.